How to Value a Combined Hospice and Home Health Agency

In healthcare M&A, few business models generate more buyer interest right now than the combined hospice and home health operation. I've spent years working on healthcare transactions, and the combined model consistently commands premium valuations because it solves a problem that standalone agencies can't: it captures the patient across the full continuum of post-acute care, from skilled nursing visits through end-of-life.

The valuation dynamics for these combined agencies are meaningfully different from either a standalone hospice agency or a standalone home health agency. The whole is genuinely worth more than the sum of its parts, and understanding why requires looking at the Medicare reimbursement mechanics, shared infrastructure economics, and cross-referral dynamics that create the synergy value.

Why the Combined Model Commands a Premium

A standalone home health agency provides skilled nursing, physical therapy, and other clinical services to patients recovering at home. Revenue per patient episode runs $3,000-$4,500 under PDGM (Patient-Driven Groupings Model). A standalone hospice agency provides palliative and end-of-life care, typically generating $150-$200 per patient per day under the Medicare Hospice Benefit, with an average length of stay of 70-90 days per patient.

The combined operation captures both revenue streams. A patient who starts with home health services — say, post-surgical rehabilitation — and later transitions to hospice care generates revenue across two distinct Medicare benefit categories. The agency doesn't have to "hand off" the patient to a competitor. The clinical team maintains the relationship, and the transition happens seamlessly.

From a buyer's perspective, this cross-referral pipeline is the single most valuable asset a combined agency possesses. It creates a built-in hospice referral source that doesn't depend on hospital discharge planners or physician relationships that might not survive an ownership change. The referrals come from within.

Valuation Multiples: 10-14x EBITDA

Combined hospice and home health agencies in the current market are trading at 10-14x EBITDAfor well-run operations with $2M+ in EBITDA. That's a meaningful premium over standalone agencies:

• Standalone home health: 6-10x EBITDA, with the higher end for agencies with strong PDGM performance and diversified payer mix.
• Standalone hospice: 8-12x EBITDA, reflecting the predictable per diem revenue model and growing demand.
• Combined hospice + home health: 10-14x EBITDA, driven by synergy value, cross-referral economics, and operational efficiency.

The premium — typically 2-3 turns above what you'd get valuing each piece separately — reflects three things buyers are paying for: the cross-referral pipeline, the shared clinical staff efficiency, and the reduced regulatory risk of having diversified revenue streams.

For a combined agency doing $8M in revenue with $2M EBITDA, that 10-14x range means an enterprise value of $20-28M. Valued separately, the home health piece at 8x and the hospice piece at 10x might total $18-22M. The combination creates $2-6M in incremental value — and that's before accounting for the operational synergies a buyer can extract post-close.

Shared Clinical Staff: The Efficiency Engine

One of the most tangible sources of value in the combined model is shared clinical infrastructure. Nurses, physical therapists, social workers, and aides can serve both the home health and hospice patient populations, creating staffing flexibility that standalone agencies can't match.

Consider the staffing math. A home health agency needs a Director of Nursing, a clinical manager, intake coordinators, schedulers, and billing staff. A hospice agency needs the same roles — plus a medical director. A combined operation shares many of these positions. The intake team handles both service lines. The billing department processes both Medicare benefit types. The clinical manager oversees both patient populations.

I typically see combined agencies operate with 15-25% lower overhead per revenue dollar compared to running the two entities separately. That overhead savings drops directly to EBITDA, which at a 10-14x multiple translates to significant enterprise value.

The staffing efficiency also helps with the biggest operational challenge in home-based care: clinician recruitment and retention. Nurses and therapists who work for a combined agency have more scheduling flexibility and varied patient populations, which reduces burnout. Lower turnover means lower recruiting costs and more consistent patient care — both of which show up in star ratings and financial performance.

Cross-Referral Value: The Hidden Asset

The internal referral pipeline from home health to hospice is the asset that sophisticated buyers value most — and the one that sellers most often underestimate.

In a standalone hospice, 60-70% of referrals typically come from hospitals and physician practices. Those referral relationships are fragile — they depend on personal relationships, discharge planner preferences, and competitive dynamics that can shift with an ownership change.

In a combined agency, 20-35% of hospice admissions can come from the home health patient population. These are patients the agency already knows, whose clinical trajectory the nurses are already tracking. The transition conversation happens naturally as part of ongoing care, not as a cold referral from an outside source.

The financial impact is substantial. Each hospice admission generates $10,000-$18,000 in revenue (based on 70-90 day average length of stay at $150-$200/day). If internal cross-referrals generate 25 additional hospice admissions per year, that's $250,000-$450,000 in incremental revenue with minimal marketing cost. At hospice-level margins of 15-20%, the EBITDA contribution is $40,000-$90,000 — which at 12x represents $500K-$1M in enterprise value from this single synergy.

What Buyers Scrutinize

Medicare compliance history. Both home health and hospice are heavily regulated by CMS. Buyers will review your survey history, any conditions of participation issues, complaint investigations, and ADR (Additional Documentation Request) denial rates. A clean compliance record is table stakes. Any history of targeted probe and educate (TPE) audits, OIG investigations, or qui tam lawsuits will either kill the deal or result in massive escrow holdbacks.

Star ratings and quality metrics. Home health star ratings (published by CMS) directly affect referral volume and increasingly affect reimbursement through value-based purchasing. Hospice quality metrics — CAHPS scores, quality reporting compliance — signal operational quality. Buyers pay premium multiples for 4-5 star agencies and discount meaningfully for agencies rated below 3 stars.

Payer mix beyond Medicare. While Medicare dominates both home health and hospice, buyers value agencies that have built Medicare Advantage, Medicaid, and private insurance volumes. The trend toward MA penetration means agencies that already have MA contracts and know how to operate under managed care are worth more than pure fee-for-service Medicare agencies.

Geographic coverage and CON status. In states with Certificate of Need (CON) requirements for hospice — like Virginia, Georgia, and Alabama — the CON itself is a valuable intangible asset. It represents a barrier to entry that protects the agency's market position. Buyers in CON states routinely pay 1-2 additional EBITDA turns for the regulatory protection.

Maximizing the Combined Platform Value

If you're operating a combined hospice and home health agency and considering a sale, here's what drives the premium:

Track cross-referral data. If you can show buyers that 25-30% of your hospice admissions originate from your home health census, you're proving the synergy value with hard data. Most agencies don't track this — the ones that do command higher multiples.

Maintain clean compliance. Invest in a compliance officer and regular internal audits. A single Medicare overpayment investigation can derail a transaction or result in 6-12 months of delayed closing while the issue resolves.

Build management depth. A combined agency that relies on the owner as both administrator of record and de facto clinical leader is a risky acquisition. Having a qualified administrator, a DON for each service line, and a strong billing manager demonstrates an organization that functions beyond the founder.

Grow the Medicare Advantage book. The shift from traditional Medicare to MA is accelerating. Agencies with established MA contracts and demonstrated ability to operate profitably under managed care are better positioned for where the market is heading — and buyers are willing to pay for that positioning.

The Bottom Line

The combined hospice and home health model is one of the most sought-after assets in healthcare M&A. The cross-referral synergies, shared clinical infrastructure, and diversified revenue streams create genuine value that buyers quantify and pay for. At 10-14x EBITDA, these businesses are trading at premium multiples — but only when the operational fundamentals are solid: clean compliance, strong star ratings, documented referral pipelines, and management teams that can operate independently of the founder. Build those pieces, and you'll be positioned to capture the full value of what the combined model offers.